Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I StudySuzanne Trudel, Simon J. Harrison, Rayan Kaedbey et al.|Blood|2021Cited by 161
Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucelSaurabh Zanwar, Doris K. Hansen, Jack Khouri et al.|Journal of Hematology & Oncology|2024Cited by 46
Phase II Clinical Trial: Ex Vivo Drug Sensitivity Testing in Parallel with Physician Selected Selinexor-Based Therapy for Multiple MyelomaZachary J. Walker, Daniel W. Sherbenou, Katie Zhou et al.|Blood|2024Cited by 1